Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.

E Palmerini,R L Jones,E Setola,P Picci,E Marchesi,R Luksch,G Grignani,M Cesari,A Longhi,M E Abate,A Paioli, Z Szucs,L D'ambrosio,K Scotlandi,F Fagioli,S Asaftei,S Ferrari

Acta oncologica (Stockholm, Sweden)（2018）

引用 41|浏览78

暂无评分

摘要

This series confirms the activity of TEMIRI in both adults and pediatric patients. This schedule offers a 71% DCR, independently of the line of chemotherapy. Predictive factors of response are ECOG and LDH.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要